Major depressive disorder (MDD) is a highly drug-treated condition that uses an array of drug classes including, but not limited to, serotonin reuptake inhibitors (SSRIs), selective serotonin/norepinephrine reuptake inhibitors (SNRIs), and—as adjunctive therapies—atypical antipsychotics. Even though the MDD drug market is entrenched with generic therapies, MDD patients’ heterogeneous response to antidepressants and/or atypical antipsychotics afford branded drugs (e.g., Trintellix [Lundbeck/Takeda], Rexulti [Otsuka Pharmaceuticals/Lundbeck]) the opportunity to be introduced into the treatment paradigm, often as later-line therapies. Given MDD’s crowded and competitive landscape, it is valuable for drug marketers and developers to understand how MDD patients are being treated using real-world data.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed MDD patients? What are the quarterly trends in prescribing among recentlytreated and newly diagnosed MDD patients?
- How have antidepressants and atypical antipsychotics been integrated into the treatment algorithm?
- What proportion of MDD patients receive drug therapy within one year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of MDD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with MDD?
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess theirsource of business and quantify areas of opportunity for increasing their brand share.